Physician profile
Jayapal Reddy
NPI 1073573903
$5,476.84
in general payments reported to CMS, 2019-2025
28 companies · $64.16 in 2025
The $64.16 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,018 · 2020: $1,134 · 2021: $1,463 · 2022: $443 · 2023: $168 · 2024: $186 · 2025: $64.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $418.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corindus INC. | $1,192.42 | 2019 | |
| Medtronic Vascular, INC. | $834.49 | 2019-2020 | |
| Inari Medical, INC. | $469.47 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $467.86 | 2019-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $362.76 | 2019-2024 | |
| Philips North America LLC | $349.59 | 2019 | |
| Amarin Pharma, INC. | $255.76 | 2019-2023 | |
| Shockwave Medical, INC | $200.49 | 2021-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Janssen Pharmaceuticals, INC | $181.10 | 2019-2021 | |
| Abbott Laboratories | $180.71 | 2019-2022 | |
| Medtronic, INC. | $162.83 | 2021-2022 | |
| Chiesi USA, INC. | $143.28 | 2020-2022 | |
| Abiomed | $121.68 | 2020-2024 | Impella |
| Cardinal Health 200 LLC | $70.74 | 2019-2021 | |
| Bridgebio Pharma, INC. | $64.16 | 2025 | Attruby |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $53.26 | 2019-2023 | |
| Cardiovascular Systems INC. | $46.53 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $45.40 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $42.88 | 2022-2023 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $39.78 | 2021 | |
| Scpharmaceuticals INC. | $33.62 | 2023 | |
| Boston Scientific Corporation | $30.01 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.78 | 2022 | |
| Astellas Pharma US INC | $24.39 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.54 | 2021 | |
| Teleflex LLC | $21.01 | 2020 | |
| Kiniksa Pharmaceuticals, Ltd. | $18.00 | 2021 | |
| W. L. Gore & Associates, INC. | $14.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayapal Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.